Cohance Life (COHANCE)

Slow Grower

FairStock Score: 44/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Current Price₹440.65
Market Cap₹16,859.15 Cr
P/E Ratio158.51
ROCE14.89%
ROE16.51%
Dividend Yield0%
Profit Growth-96.8%
Debt/Equity0.1
Sales Growth-23.1%
Free Cash Flow₹35 Cr
Promoter Holding57.49%
52-Week Range₹266.7 — ₹875
SectorPharmaceuticals & Biotechnology
Book Value₹102.03

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I wear Graham's defensive lens and Buffett's business-quality lens. Cohance has a low debt burden: Debt/Equity 0.10, ROE 16.51%, ROCE 14.89%, promoter holding 57.49%, positive FCF ₹35 Cr, Altman Z 4.32, and Piotroski 6/9. That tells me the balance sheet is not distressed and promoters have skin in the game. But the operating picture is poor: Sales growth -23.10%, profit growth -96.80%, and 5-year revenue CAGR only 7.51%. Latest quarter sales were ₹545 Cr and net profit ₹29 Cr. A ₹16,859 Cr market cap on that earnings base gives P/E 158.51, P/B 4.32, EV/EBITDA 41.32, and PEG 2.56. Even if margins recover, I am asked to pay a superlative price for a business that has not shown superlative growth. Graham Number is ₹104.77, so at ₹440.65 my margin of safety is -195.85%. DCF intrinsic value ₹0.28 is a warning that the given cash flows do not support the market price. FairStock 44/100 is mixed. The stock is down from ₹917.85 to ₹440.65, but cheapness is not the same as value; P/B 4.32 and P/E 158.51 are not defensive. I would wait for evidence that sales and profits have bottomed, and for price to approach a Graham-style valuation. A great balance sheet and low debt are not enough if the business is shrinking and the price already discounts a perfect recovery.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer